← All indications
Thrombocytosis
Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed)
Subtype terms (1)
More specific conditions that are subtypes of Thrombocytosis in the MeSH hierarchy.
- Thrombocythemia, Essential
75 drugs (45 approved, 30 experimental)
Drugs by status
Approved for this indication (1)
Phase 2 trials (7)
Phase 1 trials (3)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (26)
- Incyte
- Celgene
- Roche
- Gilead Sciences
- AOP Orphan Pharmaceuticals AG
- CTI BioPharma
- Constellation Pharmaceuticals
- EPS Corporation
- Sierra Oncology, Inc.
- National Cancer Institute (NCI)
- University of London
- French Innovative Leukemia Organisation
- Osaka University
- Queen's University, Belfast
- RWTH Aachen University
- University of Southern Denmark
- Mayo Clinic
- Icahn School of Medicine at Mount Sinai
- Medpace, Inc.
- Medical University of Vienna
- University of Texas at Houston
- Myeloproliferative Disorders Research Consoritum
- University of Paris
- Assistance Publique - Hôpitaux de Paris
- Brightech International
- PharmaEssentia Corp.
Organization Involved with Phase 2 Indications (43)
- S*BIO
- Jazz Pharmaceuticals
- YM Biosciences
- Cephalon
- Pfizer
- Sanofi
- Galena Biopharma, Inc.
- Geron Corporation
- Karyopharm Therapeutics Inc
- Promedior, Inc.
- Vifor Inc.
- Imago BioSciences
- National Heart, Lung, and Blood Institute (NHLBI)
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- Johns Hopkins University
- McGill University
- Melbourne Health
- Stanford University
- Swiss Group for Clinical Cancer Research
- Thomas Jefferson University
- University of Miami
- University of Ottawa
- University of South Florida
- University of Toronto
- University of Adelaide
- University of Bern
- University of Chicago
- +13 more
Organization Involved with Phase 1 Indications (16)
- AstraZeneca
- Eli Lilly
- Exelixis
- Sponsor GmbH
- Forbius
- University of Pittsburgh
- AIDS Malignancy Consortium
- University of Maryland
- Institut Gustave Roussy
- City of Hope National Medical Center
- State University of New York, Buffalo
- The Leukemia and Lymphoma Society
- Samus Therapeutics
- Center for Cancer Immune Therapy, Denmark
- The University of Texas, Dallas
- Myeloproliferative Neoplasm Research Consortium (MPN-RC)
Organization Involved with Other Experimental Indications (1)